JOE sign up for etocs
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Journal of Endocrinology (2005) 187, 311-325    DOI: 10.1677/joe.1.06057
© 2005 Society for Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Potts, J. T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Potts, J. T

STARLING REVIEW

    

Parathyroid hormone: past and present

John T Potts

Endocrine Unit, Department of Medicine, The Massachusetts General Hospital and Harvard Medical School, 149 Thirteenth Street, Room 4013, Charlestown, Boston, Massachusetts 02114, USA

(Requests for offprints should be addressed to John T Potts; Email: potts.john{at}mgh.harvard.edu)

Research on parathyroid hormone (PTH) has undergone four rather distinctive phases, beginning just before the turn of the 20th century. Early debates about the function of the parathyroids were resolved by 1925, when understanding the role of PTH led to comprehending the action of the glands in calcium physiology. Elucidation of the pathophysiology of hormone excess (severe bone loss) and deficiency (hypocalcemia) continued over the following decades. With the advent of advances in chemical and molecular biology, the structure of PTH and its principal receptor (PTHrP-receptor [PTHR1]) were established. Tests with purified hormonal peptide in humans led to the surprising, even paradoxical, finding that PTH can be used pharmacologically to build bone, providing a dramatic therapeutic impact on osteoporosis. These developments have stimulated the field of calcium and bone biology and posed new questions about the role of PTH as well as possible new directions in therapy.




This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
J. T. POTTS and T. J. GARDELLA
Progress, Paradox, and Potential: Parathyroid Hormone Research over Five Decades
Ann. N.Y. Acad. Sci., November 1, 2007; 1117(1): 196 - 208.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. J. Xian
Roles of Epidermal Growth Factor Family in the Regulation of Postnatal Somatic Growth
Endocr. Rev., May 1, 2007; 28(3): 284 - 296.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. S. Perrien, N. S. Akel, P. K. Edwards, A. A. Carver, M. S. Bendre, F. L. Swain, R. A. Skinner, W. R. Hogue, K. M. Nicks, T. M. Pierson, et al.
Inhibin A Is an Endocrine Stimulator of Bone Mass and Strength
Endocrinology, April 1, 2007; 148(4): 1654 - 1665.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. A. Roy, C. Nunn, H. Ming, M.-X. Zou, J. Penninger, L. A. Kirshenbaum, S. J. Dixon, and P. Chidiac
Up-regulation of Endogenous RGS2 Mediates Cross-desensitization between Gs and Gq Signaling in Osteoblasts
J. Biol. Chem., October 27, 2006; 281(43): 32684 - 32693.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Q. Fu, S. C. Manolagas, and C. A. O'Brien
Parathyroid Hormone Controls Receptor Activator of NF-{kappa}B Ligand Gene Expression via a Distant Transcriptional Enhancer.
Mol. Cell. Biol., September 1, 2006; 26(17): 6453 - 6468.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society for Endocrinology.